(TSX-V:SURG),(OTC US:SRGXF),(Other OTC:SRGXF),(Boerse Frankfurt – Freiverkehr:G6D2), Vancouver, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) — Surge Copper Corp. (TSXV: SURG) (OTCQB: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) is pleased to announce the appointment of Jennifer Anthony as Vice President, Environment & Regulatory Affairs, effective January 12, 2026. Ms. Anthony will join Surge's executive team […]

(NasdaqGM:AXSM), Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively AUVELITY(R) preliminary 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively SUNOSI(R) preliminary 4Q and full year 2025 net product revenue of $36.7 million

(NASDAQ:BCRX), -Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)- -ORLADEYO net revenue expected to be between $625 million and $645 million in 2026- -BioCryst expects continued non-GAAP profitability in 2026 even after expected close of the proposed acquisition of

(NYSE:HIW), _____________________________________ Acquires Bloc83 in CBD Raleigh in Joint Venture with the North Carolina Investment Authority$21.0M Total Investment (at HIW 10% Share)492,000 Square Feet, 97% Leased_____________________________________ Acquires The Terraces in Preston Center BBD in Dallas in Joint Venture with Granite Properties$87.4M Total Investment (at HIW 80% Share)173,000 Square Feet, 98% Leased_____________________________________ Acquisitions to be Funded

Financing includes $63.5M Series B equity and $20M strategic non-dilutive credit facility Capital supports accelerated scaling amid strong commercial traction with leading biopharmaceutical developers of next-generation precision medicines BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) — Precede Biosciences, a precision diagnostics and data company focused on enabling the next generation of precision medicines, today announced that

(NasdaqGM:ORKA), ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in

(NASDAQ:AUTL), Company expects preliminary unaudited AUCATZYL(R) net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025 Autolus anticipates full year 2026 AUCATZYL(R) net product revenue of $120 million to $135 million Independent real-world AUCATZYL(R) data from ROCCA consortium confirm high level of

(NASDAQ:ZUMZ), North America Comparable Sales Increase 6.5%Adjusting Fourth Quarter Outlook Including Raising EPS Guidance LYNNWOOD, Wash., Jan. 12, 2026 (GLOBE NEWSWIRE) — Zumiez Inc. (NASDAQ: ZUMZ) a leading specialty retailer of apparel, footwear, equipment and accessories for young men and women, today announced that the Company's comparable sales for the nine-week period ended January 3,

(NASDAQ:NDLS), BROOMFIELD, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) — Noodles & Company (Nasdaq: NDLS) today released preliminary, unaudited sales results for the fourth fiscal quarter ended December 30, 2025. Preliminary Fourth Quarter of 2025 Sales Results Compared to the Fourth Quarter of 20241: Fourth quarter system-wide comparable sales increased 6.6%, comprised of a 7.3% increase

(NasdaqGM:TARA), On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026 Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support